

Geoffrey Y Ku

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2608990/publications.pdf>

Version: 2024-02-01

89
papers

7,460
citations

201575

27
h-index

60583

81
g-index

93
all docs

93
docs citations

93
times ranked

11014
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction FOLFOX and PET-Directed Chemoradiation for Locally Advanced Esophageal Adenocarcinoma. <i>Annals of Surgery</i> , 2023, 277, e538-e544.	2.1	7
2	Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma. <i>Annals of Surgery</i> , 2022, 276, 1017-1022.	2.1	10
3	Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 255-265.	1.1	1
4	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	3.0	3
5	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptorâ€“Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
6	The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2669-2678.	3.2	6
7	Approach to Resectable Gastric Cancer: Evolving Paradigm of Neoadjuvant and Adjuvant Treatment. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1044-1058.	1.3	4
8	PD-L1 expression and overall survival in Asian and western patients with gastric cancer. <i>Future Oncology</i> , 2022, 18, 2623-2634.	1.1	2
9	Can 18F-FDG PET/CT Radiomics Features Predict Clinical Outcomes in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma?. <i>Cancers</i> , 2022, 14, 3035.	1.7	6
10	Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 836-843.e1.	0.4	62
11	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repairâ€“proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	3.2	51
12	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. <i>Annals of Surgical Oncology</i> , 2021, 28, 4829-4838.	0.7	14
13	Oligometastases After Curative Esophagectomy Are Not One Size Fits All. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1775-1781.	0.7	9
14	Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. <i>Annals of Surgical Oncology</i> , 2021, 28, 3532-3544.	0.7	17
15	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. <i>Annals of Surgical Oncology</i> , 2021, 28, 7040-7050.	0.7	0
16	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. <i>Clinical Cancer Research</i> , 2021, 27, 3491-3498.	3.2	8
17	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. <i>JAMA Network Open</i> , 2021, 4, e2114753.	2.8	15
18	A nutritional management algorithm in older patients with locally advanced esophageal cancer. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	2

#	ARTICLE	IF	CITATIONS
19	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. <i>Cancer</i> , 2021, 127, 4393-4402.	2.0	24
20	Prognostic significance of "inflamed" gene expression profile and PD-L1 expression in patients with esophageal cancer. <i>Cancer Medicine</i> , 2021, 10, 8365-8376.	1.3	6
21	Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 846-854.	3.2	90
22	Cancer of the Esophagus. , 2020, , 1174-1196.e6.		5
23	Role of Imaging in Esophageal Cancer Management in 2020: Update for Radiologists. <i>American Journal of Roentgenology</i> , 2020, 215, 1072-1084.	1.0	28
24	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 821-831.	5.1	243
25	Regorafenib in Combination with First-Line Chemotherapy for Metastatic Esophagogastric Cancer. <i>Oncologist</i> , 2020, 25, e68-e74.	1.9	10
26	Next generation sequencing in gastric or gastroesophageal adenocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2020, 5, 56-56.	1.5	5
27	Immunotherapy in Esophageal Cancer. , 2020, , 289-310.		0
28	Survival Following Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?. <i>Annals of Surgery</i> , 2020, , .	2.1	5
29	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6160-6169.	3.2	73
30	Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. <i>Journal of Thoracic Disease</i> , 2019, 11, 1536-1545.	0.6	20
31	Maximizing response: a case report of salvage chemotherapy after immune checkpoint inhibition in a patient with previous chemo-refractory metastatic esophageal carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 367-372.	0.6	5
32	The Current Status of Immunotherapies in Esophagogastric Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 323-338.	0.9	9
33	Efficacy of Combined VEGFR1-3, PDGF α/β , and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3811-3817.	3.2	10
34	Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders. <i>Journal of Thoracic Oncology</i> , 2019, 14, 540-546.	0.5	15
35	Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. <i>Journal of Thoracic Disease</i> , 2019, 11, S1855-S1860.	0.6	1
36	Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 11-22.	0.9	5

#	ARTICLE	IF	CITATIONS
37	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
38	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
39	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2018, 4, e180013.	3.4	1,350
40	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2710-2721.e3.	0.4	41
41	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	7.7	275
42	Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?. <i>Journal of Thoracic Disease</i> , 2018, 10, 6407-6411.	0.6	8
43	Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. <i>BMC Cancer</i> , 2018, 18, 693.	1.1	68
44	Neoadjuvant and Adjuvant Therapy. , 2018, , 55-63.		0
45	Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 241-256.	0.6	4
46	The Current Status of Immunotherapies in Esophagogastric Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 277-292.	0.6	4
47	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. <i>Lancet Oncology</i> , The, 2017, 18, e243.	5.1	1
48	Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. <i>The Cochrane Library</i> , 2017, 2017, CD010511.	1.5	60
49	Systemic therapy for esophagogastric cancer: targeted therapies. <i>Chinese Clinical Oncology</i> , 2017, 6, 48-48.	0.4	29
50	Systemic therapy for esophageal cancer: chemotherapy. <i>Chinese Clinical Oncology</i> , 2017, 6, 49-49.	0.4	55
51	Systemic therapy for esophagogastric cancer: immune checkpoint inhibition. <i>Chinese Clinical Oncology</i> , 2017, 6, 53-53.	0.4	5
52	Preface on Esophagus Cancer. <i>Chinese Clinical Oncology</i> , 2017, 6, 44-44.	0.4	1
53	Phase II study of bevacizumab and preoperative chemoradiation for esophageal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 828-837.	0.6	6
54	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2083-2090.	2.0	30

#	ARTICLE	IF	CITATIONS
55	Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 165-171.	0.9	22
56	Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1658-1665.	2.9	15
57	Emerging mAbs for the treatment of esophagogastric cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 63-74.	1.0	1
58	Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1508-1515.	0.7	26
59	Long-Term Survival With Salvage Surgery for Recurrent Esophageal Adenocarcinoma After Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3854-3857.	0.8	7
60	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. <i>PLoS ONE</i> , 2015, 10, e0134731.	1.1	38
61	The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. , 2015, , 203-220.		0
62	Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 126-130.	0.6	6
63	Management of gastric cancer. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 596-602.	1.0	19
64	Prognostic Significance of Targetable Angiogenic and Growth Factors in Patients Undergoing Resection for Gastric and Gastroesophageal Junction Cancers. <i>Annals of Surgical Oncology</i> , 2014, 21, 1130-1137.	0.7	29
65	Adjuvant (Postoperative) Therapy for Esophageal Cancer. <i>Thoracic Surgery Clinics</i> , 2013, 23, 525-533.	0.4	11
66	Emerging tyrosine kinase inhibitors for esophageal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 219-230.	1.0	9
67	Chemotherapeutic Options for Gastroesophageal Junction Tumors. <i>Seminars in Radiation Oncology</i> , 2013, 23, 24-30.	1.0	10
68	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
69	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. <i>Lancet Oncology</i> , The, 2012, 13, e470-e481.	5.1	70
70	Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 231-238.	1.1	37
71	Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. <i>Cancer</i> , 2012, 118, 2820-2827.	2.0	67
72	Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. <i>Gastrointestinal Cancer Research: GCR</i> , 2012, 5, 85-92.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting. <i>Cancer</i> , 2010, 116, 1767-1775.	2.0	405
74	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. <i>Clinical Cancer Research</i> , 2010, 16, 2861-2871.	3.2	404
75	Esophagogastric cancer: Targeted agents. <i>Cancer Treatment Reviews</i> , 2010, 36, 235-248.	3.4	52
76	Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. <i>Cancer Immunity</i> , 2010, 10, 1.	3.2	32
77	Phase I Study of Weekly Cisplatin, Bolus Fluorouracil and Escalating Doses of Irinotecan in Advanced Solid Tumors. <i>Cancer Investigation</i> , 2009, 27, 402-406.	0.6	1
78	Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. <i>Cytotherapy</i> , 2009, 11, 912-922.	0.3	35
79	Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. <i>Surgical Oncology Clinics of North America</i> , 2009, 18, 533-546.	0.6	11
80	Preoperative Therapy for Esophageal Cancer. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 135-152.	1.0	13
81	Successful Treatment of Esophageal Cancer with Airway Invasion with Induction Chemotherapy and Concurrent Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2009, 4, 432-434.	0.5	8
82	Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. <i>Cancer Immunity</i> , 2009, 9, 5.	3.2	56
83	Phase II trial of sequential paclitaxel and 1-h infusion of bryostatin-1 in patients with advanced esophageal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 875-880.	1.1	50
84	CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20410-20415.	3.3	322
85	Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1953-1964.	1.1	4
86	Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. <i>Annals of Oncology</i> , 2008, 19, 533-537.	0.6	93
87	Preoperative therapy in esophageal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 371-9.	0.3	7
88	Successful Treatment of Leptomeningeal Disease in Colorectal Cancer With a Regimen of Bevacizumab, Temozolomide, and Irinotecan. <i>Journal of Clinical Oncology</i> , 2007, 25, e14-e16.	0.8	18
89	Esophageal Cancer: Adjuvant Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2007, 13, 162-167.	1.0	10